In this video, David Raben, MD, of the University of Colorado Cancer Center, highlights selected studies on the treatment of HPV-positive head and neck cancer presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.
Raben was the discussant for a head and neck cancer session that featured the following abstracts:
• Quantification of HPV-16 in circulating tumor DNA during de-intensified chemoradiotherapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (abstract 92)
• Induction chemotherapy followed by concurrent chemoradiation vs concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal cancer with low-neck or N3 disease (abstract 93)
• Nodal radiographic prognostic factors in the new stage I p16-positive oropharyngeal cancer of the AJCC 8th edition: is all N1 disease the same? (abstract 293)
• Long-term survival in oligometastatic head and neck cancer (abstract 296)